Johnson & Johnson has applied to the U.S. Food and Drug Administration (FDA) for approval of their coronary ticker booster dose. News AFP.
The pharmaceutical company made the request to the FDA on Tuesday, local time. This dose will be given to persons above, 18 years of age if approved.
Mathai Mammen, global head of research and development at Johnson & Johnson, said: “Those who have taken one dose of our corona vaccine are given a booster dose. which increases the body’s immune system by 94 percent. Tests have shown that.
Johnson & Johnson says taking a booster dose six months after the first dose of their vaccine strengthens the immune system. Experiments have shown that the amount of antibodies in the body increases 9 times just 1 week after taking the booster dose. After 4 weeks the antibody level increased 12 times. This rate has been found to be the same for people of all ages.
The FDA said yesterday that members of the agency’s advisory committee will meet on October 14 to discuss approving the booster dose of the modern ticker. The next day, on October 15, they will discuss Johnson & Johnson’s booster dose.
Last August, the administration of US President Joe Biden announced plans to implement a booster dose of Pfizer and Modern Corona Ticker.
The FDA has already approved the use of Pfizer’s corona ticker booster dose in people over the age of 65 in the United States. At the same time, the use of this vaccine booster dose has been approved in the country for adults at high risk of serious diseases and people at high risk of coronary heart disease. Last month, President Biden Pfizer took a ticker booster dose.